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chemotherapy regimen containing cyclophosphamide, dexamethasone, thalidomide, and bortezomib. After 2 cycles, his anemia (hemoglobin 102 g/L) and uremia (serum creatinine -1.6 mg/dl) improved, and SFLC assay showed >50% reduction in κ light chain. He is planned for maximal disease reduction with 4-6 cycles of chemotherapy followed by autologous hematopoietic stem cell transplant.
The case exemplifies various difficulties in diagnosing and categorizing MM. The absence of monoclonal protein in serum 
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Image A 53-year-old gentleman with no previous comorbidities presented with complaints of increased frequency of micturition, low backache, and easy fatiguability of 1-month duration. The clinical examination revealed pallor. His hemogram showed anemia (hemoglobin of 65 g/L, total leukocyte count of 8.8 × 10 9 /L, platelet count of 250 × 10 9 /L, and normal differential leukocyte count) and very high erythrocyte sedimentation rate (96 mm/1 st h). Serum creatinine was raised (67 mg/L). Workup for a possible diagnosis of multiple myeloma (MM) revealed lytic lesions in the skull on roentgenogram. β2 microglobulin (6.8 mg/L) and lactate dehydrogenase (410 IU/L) were raised. However, serum calcium (96 g/L) was normal; serum protein electrophoresis, urine protein electrophoresis as well as immunofixation electrophoresis (IFE) using antibodies against IgG, IgA, IgM heavy chains, and kappa (κ) and lambda (λ) light chains did not reveal monoclonal protein. Bone marrow aspirate and biopsy was hypercellular with 75% cells showing lymphoplasmacytic morphology [ Figure 1a ]. The morphology favored a lymphoproliferative disorder over MM. However, on six-color flow cytometry (antibodies from BD Biosciences, SanJose, CA), the immunophenotype was consistent with clonal plasma cells (CD38pos, CD138pos, CD19pos, CD20neg, CD45pos, CD56pos, CD81neg, CD27neg, CD28neg, CD117neg, and CD200neg) but with lack of expression of cytoplasmic light chains. 
: (a) Bone marrow aspirate smear showing predominantly cells with lymphocytic or lymphoplasmacytic morphology (May-Grunwald Giemsa ×100) (inset shows cells at ×400); (b) Fluorescence in situ hybridization using dual fusion probe showing IgH/cyclin D1 translocation (white arrow)
b a and urine even on sensitive IFE together with lymphoplasmacytic morphology and IgH/cyclin D1 translocation can lead to an erroneous diagnosis. It has been observed that free κ light chain can be missed on IFE, even when present in quantities above the expected threshold. [1] The real diagnostic utility of SFLC arises in such cases which help in the distinction of so-called "oligosecretory" or "free light chain (FLC) restricted" MM from true nonsecretory MM. [2] This distinction is important as the nonsecretory myelomas less frequently lead to renal failure. [3] The SFLC assay can also be used for disease monitoring in the FLC-restricted cases. [4] MM with lymphoplasmacytic morphology is rare constituting approximately 3% of all myelomas [5] but strongly associated with IgH/cyclin D1 translocation. [6] These cases pose a diagnostic challenge for the hematopathologist and can be easily mistaken for a lymphomatous infiltration of the bone marrow, especially in the absence of classical clinical and laboratory features. The judicious use of flow cytometry using a proper panel of antibodies proves to be of immense help in reaching a correct diagnosis in such cases. A few studies have also shown that myelomas with lymphoplasmacytic morphology have a low monoclonal protein component. [5, 6] In conclusion, the present case highlights the need for clinicians and pathologists to recognize that MM can show atypical clinical and laboratory features masquerading as lymphomas. The judicious use of flow cytometry and SFLC assay in the workup improves the accuracy of diagnosis and categorization of suspected plasma cell neoplasms.
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